42. 結節性多発動脈炎 Polyarteritis nodosa Clinical trials / Disease details
臨床試験数 : 15 / 薬物数 : 26 - (DrugBank : 16) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-004668-71-ES (EUCTR) | 13/10/2016 | 05/08/2016 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | ||
| 2 | EUCTR2013-004668-71-IT (EUCTR) | 01/08/2016 | 14/07/2015 | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | ||
| 3 | EUCTR2013-004668-71-GB (EUCTR) | 25/09/2014 | 25/09/2014 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 17.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Croatia;Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Germany;Netherlands;Sweden | ||
| 4 | NCT00751517 (ClinicalTrials.gov) | September 2008 | 11/9/2008 | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. | Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis;Polyarteritis Nodosa | Drug: Methotrexate;Drug: Cyclophosphamide | University of Parma | NULL | Active, not recruiting | 18 Years | 80 Years | Both | Phase 2 | Italy | |
| 5 | NCT00307671 (ClinicalTrials.gov) | July 2005 | 27/3/2006 | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants | Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa | Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 65 Years | N/A | Both | 108 | Phase 4 | France |
| 6 | NCT00006055 (ClinicalTrials.gov) | March 2000 | 5/7/2000 | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation | Fairview University Medical Center | NULL | Active, not recruiting | 1 Year | 55 Years | Both | 10 | N/A | United States | |
| 7 | NCT00400075 (ClinicalTrials.gov) | July 1996 | 14/11/2006 | CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors | CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients | Polyarteritis Nodosa;Microscopic Polyangiitis | Drug: azathioprine;Drug: cyclophosphamide | Hospices Civils de Lyon | NULL | Active, not recruiting | 15 Years | 90 Years | Both | 124 | Phase 4 | Switzerland |
| 8 | EUCTR2013-004668-71-PT (EUCTR) | 16/02/2016 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 18.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | |||
| 9 | EUCTR2013-004668-71-BE (EUCTR) | 12/04/2017 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden |